Bristol Myers Squibb posts new data of investigational compounds (BMS-790052 and BMS-650032) and their combination with old therapies such as pegylated interferon and ribavirin. (Data posted) and (press release)
Abbott also said in press release that Abbott and Enanta Pharmaceuticals today announced positive results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C (HCV) infection.
Telaprevir is leading in race of Hepatitis C treatment which is from Vertex Pharmaceuticals and it is protected by PCT application no WO2002/018369 (est. expiry would be 31/08/2021). PCT application ‘369 is originally filed by Eli Lilly and currently assigned to Vertex (in many countries).